Nanoviricides (NNVC) Capital Expenditures Growth (1y) (2011 - 2025)
Nanoviricides (NNVC) Capital Expenditures Growth (1y) (2011 - 2025) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Capex Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | -22.99% |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 9.68% |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 1,133.33% |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | -37.81% |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 142.64% |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -3.37% |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -73.62% |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 22,433.30% |
| 10 | Nanoviricides | 28.74 Mn | 25.53 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -100.69% |
| Sep 30, 2025 | 91.88% |
| Jun 30, 2025 | -138.73% |
| Dec 31, 2024 | 270.77% |
| Sep 30, 2024 | -11,816.22% |
| Jun 30, 2024 | 3,252.49% |
| Mar 31, 2024 | -25.81% |
| Dec 31, 2023 | 252.04% |
| Sep 30, 2023 | 99.46% |
| Jun 30, 2023 | -106.40% |
| Mar 31, 2023 | -102.94% |
| Dec 31, 2022 | 62.66% |
| Sep 30, 2022 | -128.18% |
| Jun 30, 2022 | -69.72% |
| Mar 31, 2022 | 10,749.53% |
| Dec 31, 2021 | 43.20% |
| Sep 30, 2021 | -30.50% |
| Jun 30, 2021 | 6,607.79% |
| Mar 31, 2021 | 39.56% |
| Dec 31, 2020 | -994.76% |